SCHEMBL2881177

SCHEMBL2881177

CC(C)(C)OC(=O)N1CCN(c2ccc(Oc3ccccc3)cc2)CC1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GPR119 Q8TDV5 5/20 0.62
MAPT P10636 4/20 0.61
LMNA P02545 2/20 0.61
ALDH1A1 P00352 2/20 0.61
NAMPT P43490 1/20 0.59
SMN1; SMN2 Q16637 3/20 0.55
ALOX15 P16050 1/20 0.54
PDK2 Q15119 1/20 0.53
ESRRB O95718 1/20 0.53
ESR1 P03372 1/20 0.53
ESRRA P11474 1/20 0.53
ESRRG P62508 1/20 0.53
L3MBTL1 Q9Y468 1/20 0.52
HTT P42858 2/20 0.52
CRHBP P24387 1/20 0.52
CRHR2 Q13324 1/20 0.52
KDM4E B2RXH2 1/20 0.52
NPC1 O15118 1/20 0.52
GALR3 O60755 1/20 0.52
NR2F2 P24468 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1458887 0.89 GPR119 (0.76) GPR119MAPTLMNAALDH1A1NAMPT
SCHEMBL2884134 0.88 MAPT (0.60) GPR119MAPTLMNAALDH1A1NAMPT
SCHEMBL5573222 0.87 MAPT (0.76) GPR119MAPTLMNAALDH1A1NAMPT
SCHEMBL5542227 0.86 GPR119 (0.65) GPR119MAPTLMNAALDH1A1NAMPT
SCHEMBL1458624 0.85 L3MBTL1 (0.73) GPR119MAPTLMNAALDH1A1NAMPT
SCHEMBL2097736 0.85 MAPT (0.65) GPR119MAPTLMNAALDH1A1NAMPT
Diphenylether SCHEMBL27989772 0.84 MEN1 (0.55) GPR119MAPTSMN1; SMN2KDM4ENPC1
SCHEMBL3147292 0.84 MAPT (0.88) MAPTLMNAALDH1A1SMN1; SMN2HTT
SCHEMBL2883449 0.84 GPR119 (0.58) GPR119MAPTLMNAALDH1A1NAMPT
SCHEMBL5466989 0.84 NAMPT (0.59) GPR119MAPTLMNAALDH1A1NAMPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7750012-B2 Biaryl nitrogen-heterocycle inhibitors of LTA4H for treating inflammation DECODE GENETICS EHF (IS) 2010-07-06 US disclosed
EP-1968961-A2 BIARYL NITROGEN HETEROCYCLE INHIBITORS OF LTA4H FOR TREATING INFLAMMATION Decode Genetics EHF (IS) 2008-09-17 EP disclosed
WO-2007078335-A2 BIARYL NITROGEN HETEROCYCLE INHIBITORS OF LTA4H FOR TREATING INFLAMMATION DECODE GENETICS, EHF. (IS) 2007-07-12 WO disclosed
US-20070149544-A1 BIARYL NITROGEN-HETEROCYCLE INHIBITORS OF LTA4H FOR TREATING INFLAMMATION DECODE CHEMISTRY, INC. (US) 2007-06-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070149544-A1 BIARYL NITROGEN-HETEROCYCLE INHIBITORS OF LTA4H FOR TREATING INFLAMMATION LTA4H, LTC4S, LTB4R GPR119 2123/4885MAPT 4389/4885LMNA 1768/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.